Tilray Inc (NASDAQ:TLRY – Get Free Report) CFO Carl A. Merton purchased 26,000 shares of the business’s stock in a transaction on Friday, November 15th. The shares were acquired at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the completion of the acquisition, the chief financial officer now directly owns 26,000 shares in the company, valued at approximately $35,360. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Tilray Stock Down 0.8 %
Shares of NASDAQ:TLRY opened at $1.31 on Wednesday. The business’s 50 day moving average is $1.64 and its 200 day moving average is $1.76. Tilray Inc has a 12-month low of $1.28 and a 12-month high of $2.97. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -4.85 and a beta of 2.14. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08.
Tilray (NASDAQ:TLRY – Get Free Report) last posted its quarterly earnings data on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $200.00 million for the quarter, compared to the consensus estimate of $218.70 million. Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.10) EPS. On average, sell-side analysts forecast that Tilray Inc will post -0.14 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tilray
Analyst Ratings Changes
Separately, Roth Mkm reduced their target price on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research note on Friday, October 11th.
Get Our Latest Stock Analysis on TLRY
About Tilray
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Featured Articles
- Five stocks we like better than Tilray
- The 3 Best Fintech Stocks to Buy Now
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Learn Technical Analysis Skills to Master the Stock Market
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- There Are Different Types of Stock To Invest In
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.